Mogrosides belong to a class of molecules known as cucurbitane-type triterpene glycosides, with mogroside V constituting the predominant variant found in the fruit of Siraitia grosvenorii. These compounds have attracted enormous commercial interest as sugar substitutes for individuals managing diabetes, obesity, or metabolic syndrome, given their negligible caloric contribution and minimal impact on blood glucose concentrations. Regulatory agencies including the United States Food and Drug Administration have classified monk fruit extracts as generally recognized as safe, and an acceptable daily intake has been formally established. However, the review’s authors contend that the therapeutic significance of these molecules transcends their role as sweetening agents. Drawing upon accumulated evidence from cell culture experiments, animal models, and molecular signaling studies, they map an intricate network through which mogrosides appear to influence pathways central to cancer initiation, growth, metastasis, and immune surveillance, positioning them as candidates whose relevance extends well beyond the food industry into the domain of integrative oncology.

At the core of the review’s argument lies the phenomenon of metabolic reprogramming, first characterized by Otto Warburg nearly a century ago. Normal differentiated cells primarily generate energy through mitochondrial oxidative phosphorylation, efficiently extracting adenosine triphosphate from glucose in the presence of oxygen. Cancer cells, by contrast, preferentially metabolize glucose through glycolysis even under aerobic conditions—a metabolic signature known as the Warburg effect that enables rapid biosynthesis of the macromolecules required for cell division. This glycolytic shift produces substantial quantities of lactate, which accumulates in the tumor microenvironment and creates an acidic milieu that impairs immune cell function, promotes tissue invasion, stimulates new blood vessel formation, and fosters resistance to both chemotherapy and radiotherapy. The authors compile evidence from multiple preclinical investigations indicating that mogrosides directly counteract this metabolic rewiring. Their analysis indicates that mogrosides activate AMP-activated protein kinase, or AMPK, a highly conserved enzyme that functions as the cell’s primary energy sensor and master metabolic regulator, coordinating a systemic shift away from anabolic biosynthesis and toward catabolic pathways that generate energy through the breakdown of stored macromolecules.

The activation of AMPK by mogrosides initiates a cascade of downstream events with profound implications for tumor biology. AMPK directly phosphorylates and inhibits mechanistic target of rapamycin, abbreviated mTOR, a serine/threonine kinase that integrates growth factor, nutrient, and energy signals to control protein synthesis, lipid metabolism, and cellular growth. The mTOR pathway operates downstream of phosphoinositide 3-kinase and protein kinase B, forming the PI3K/AKT/mTOR signaling axis that is constitutively hyperactivated in the majority of human malignancies. By suppressing this signaling cascade, mogrosides reduce ribosomal biogenesis, cap-dependent translation, and cell cycle progression, thereby constraining the synthetic machinery that rapidly dividing cells require for uncontrolled proliferation. Simultaneously, AMPK phosphorylates acetyl-CoA carboxylase, the rate-limiting enzyme in fatty acid biosynthesis, effectively shutting down de novo lipogenesis. Cancer cells depend heavily on lipid synthesis to construct membranes for daughter cells, generate lipid-derived signaling molecules, and maintain membrane fluidity, and by blocking this pathway, mogrosides deprive tumors of essential structural and regulatory components. The review further documents that mogrosides downregulate hypoxia-inducible factor 1 alpha, a transcription factor that accumulates under the hypoxic conditions characteristic of solid tumors and drives expression of glucose transporters and glycolytic enzymes, thereby reinforcing the metabolic shift that mogrosides oppose.

The suppression of lactate accumulation represents another critical mechanism through which mogrosides may undermine tumor progression and restore immune competence within the tumor microenvironment. Lactate does not merely acidify the extracellular space; it actively recruits macrophages toward a pro-tumor M2 phenotype, inhibits the cytotoxic activity of CD8-positive T cells and natural killer cells, promotes the expansion of immunosuppressive regulatory T cells, and upregulates matrix metalloproteinases that degrade the extracellular matrix and facilitate invasion. By curtailing lactate production through inhibition of glycolytic flux, mogrosides may indirectly reverse multiple immunosuppressive features of the tumor microenvironment. This metabolic intervention could create conditions more favorable for endogenous antitumor immunity and potentially enhance the efficacy of immunotherapeutic approaches that depend upon functional T cell responses. The authors emphasize that this mechanism links the metabolic and immunological effects of mogrosides into a coherent pharmacological profile consistent with their proposed role as bifunctional regulators capable of simultaneously targeting both axes of tumor biology.

Beyond their metabolic effects, mogrosides appear to directly modulate immune signaling pathways that tumors exploit for survival and propagation. The review identifies signal transducer and activator of transcription 3, or STAT3, and nuclear factor kappa B, or NF-κB, as two transcription factors whose persistent activation in tumor cells promotes inflammation, proliferation, angiogenesis, metastasis, and immune evasion. Constitutively phosphorylated STAT3 drives expression of genes encoding pro-inflammatory cytokines including interleukin-6, interleukin-10, and tumor necrosis factor-alpha, which in turn create autocrine and paracrine signaling loops that sustain tumor-promoting inflammation and paracrine suppression of antitumor immunity. NF-κB, another transcription factor frequently hijacked by malignant cells, governs the expression of genes controlling inflammation, resistance to apoptosis, and immune suppression through mechanisms involving inhibitor of kappa B kinase phosphorylation and subsequent transcriptional activation of target genes. Evidence compiled in the review indicates that mogrosides suppress both STAT3 and NF-κB signaling, thereby reducing production of inflammatory mediators and dampening the chronic inflammatory state that characterizes many solid tumors and facilitates disease progression.

Perhaps the most clinically significant immunological finding concerns the downregulation of programmed death-ligand 1, commonly abbreviated PD-L1, a cell surface protein that tumor cells deploy to evade cytotoxic T lymphocyte-mediated destruction. PD-L1 binds to its receptor PD-1 on activated T cells and delivers an inhibitory signal that paralyzes antitumor immune responses. The extraordinary clinical success of immune checkpoint inhibitors such as pembrolizumab and nivolumab, which block this interaction, has validated PD-L1 as a therapeutic target; however, primary and acquired resistance remain formidable obstacles, and many tumors fail to respond or eventually progress despite initial benefit. The review presents evidence that mogrosides reduce PD-L1 expression through suppression of upstream signaling pathways including JAK/STAT3 and PI3K/AKT, suggesting a potential mechanism by which these compounds could sensitize tumors to checkpoint blockade immunotherapy or reduce baseline immunosuppressive pressure within the tumor microenvironment. The authors additionally describe interference with the MAPK/ERK signaling cascade, a mitogen-activated protein kinase pathway that transmits proliferative signals from cell surface growth factor receptors to the nucleus and is hyperactivated in approximately one-third of all human cancers through mutations at various nodes including RAS, RAF, and MEK.

The anti-metastatic properties of mogrosides further encompass inhibition of epithelial-mesenchymal transition, a developmental program that cancer cells appropriate to detach from the primary tumor mass, invade surrounding stromal tissue, intravasate into blood vessels or lymphatic channels, and establish metastatic colonies at distant organs. This process is orchestrated by transcription factors including Snail, Slug, Twist, and zinc finger E-box-binding homeobox factors, whose expression drives loss of epithelial markers such as E-cadherin and acquisition of mesenchymal markers including N-cadherin and vimentin. Studies cited in the review indicate that mogroside treatment reduces the expression of these transition-promoting transcription factors across multiple cancer models, preserving epithelial characteristics and limiting invasive potential. Additionally, mogrosides suppress matrix metalloproteinase-9 and matrix metalloproteinase-2, zinc-dependent endopeptidases that cleave components of the extracellular matrix and basement membrane, clearing the physical barriers that ordinarily contain tumor cells and enabling metastatic dissemination to distant anatomical sites.

The concept of exploiting dietary compounds as therapeutic adjuncts in oncology has gained considerable traction over recent decades, driven partly by recognition that many cancers develop resistance to single-agent targeted therapies and that combination approaches engaging multiple pathways simultaneously may yield more durable clinical responses. Mogrosides, by virtue of their apparent capacity to simultaneously modulate metabolic reprogramming, immune checkpoint expression, inflammatory signaling, and metastatic machinery, exemplify the polypharmacology paradigm in which a single molecular class engages multiple biological targets. The review’s authors frame this dual functionality as the defining characteristic that distinguishes mogrosides from many single-target agents, positioning them as candidates for integration into multimodal treatment regimens alongside surgery, chemotherapy, radiotherapy, or immunotherapy. The exceptionally favorable safety profile of these compounds, established through decades of dietary use and formal toxicological assessment including establishment of an acceptable daily intake, provides a considerable advantage over many synthetic investigational drugs whose inherent toxicity frequently limits the doses patients can tolerate, restricting their therapeutic window.

Despite the mechanistic promise documented throughout the review, the authors temper their conclusions with significant caveats. Most supporting evidence derives from in vitro cell culture experiments and rodent models, which do not always translate predictably to human physiology. Questions surrounding the bioavailability of orally administered mogrosides—specifically whether pharmacologically active concentrations can be achieved in tumor tissue following dietary consumption—remain unresolved. The gut microbiome metabolizes mogrosides into secondary compounds whose pharmacological profiles may differ substantially from the parent molecules, complicating predictions about in vivo efficacy. Furthermore, no clinical trials have yet specifically evaluated mogrosides as anticancer agents in human subjects. The authors call for systematic pharmacokinetic studies, drug interaction assessments, and ultimately well-designed controlled clinical trials to determine whether the molecular mechanisms they have catalogued can be translated into measurable therapeutic benefit for cancer patients. Nevertheless, as understanding of the metabolic and immunological dimensions of malignancy continues to deepen, mogrosides exemplify how molecules initially valued for their sensory properties may harbor deeper biological significance with potential implications for cancer prevention, adjuvant treatment, and improved patient outcomes.

The research team employed a robust systems biology approach, integrating bioinformatics tools, molecular modeling, and biological assays to decode the mechanisms of neoschaftoside. By leveraging these methodologies, they operated on a multi-faceted level, mapping out the interactions between the drug, cancer pathways, and the cellular environment. This holistic perspective is pivotal in understanding complex biological phenomena, especially in cancer biology where multiple signaling pathways often converge and diverge in unpredictable manners.

Ailanthus altissima, commonly known as the Tree of Heaven, has long been used in traditional medicine, particularly in Eastern cultures. The study’s authors embarked on an extensive exploration to validate its therapeutic potential, identifying neoschaftoside as a key component with anti-cancer properties. Through an array of experimental techniques, including cell viability assays and molecular docking studies, they meticulously documented the effects of neoschaftoside on various lung cancer cell lines.

The findings provide compelling evidence for neoschaftoside’s role as an effective agent against lung cancer. By selectively inducing apoptosis in malignant cells, the compound appeared to trigger a cascade of events leading to cell death without adversely affecting surrounding normal cells. This selective cytotoxicity is a coveted quality in cancer therapeutics, as it could allow for more effective treatments with fewer side effects compared to conventional chemotherapeutic agents that often compromise healthy tissue.

Previous studies have hinted at the potential of natural compounds as therapeutic agents in cancer treatment, but the challenge lies in understanding the detailed mechanisms by which they exert their effects. This study addresses that gap, elucidating the signaling pathways influenced by neoschaftoside and its interactions with molecular targets within cancer cells. The authors detail how neoschaftoside affects critical pathways, including those involved in cell cycle regulation and stress response, thus providing a clearer picture of its role in cancer biology.

Moreover, the systems biology approach employed in this study emphasizes the intricate relationship between various biological networks. The researchers utilized advanced computational models to predict how neoschaftoside would interact with known cancer-related proteins. Such predictive modeling is critical, as it can guide future experimental designs and theragnostic strategies tailored to individual patients.

In an age of personalized medicine, the quest for targeted therapeutics is paramount. The molecular insights gained from this research could pave the way for novel treatment regimens specifically designed for lung cancer patients. By understanding how neoschaftoside interacts with specific genetic and molecular profiles associated with lung cancer, clinicians may be able to develop more precise and effective therapeutic strategies.

Another significant aspect of the study is its implications for drug development. The findings reinforce the notion that natural products, often overlooked in modern pharmacology, hold vast potential for developing new cancer therapies. With a wealth of diverse compounds responsible for various biological activities, the biological properties of neoschaftoside could inspire further explorations into other phytochemicals for potential anti-cancer activities.

Additionally, the environmental and economic sustainability of utilizing plant-derived compounds cannot be overlooked. Given the challenges of drug resistance and toxicity associated with many existing cancer treatments, naturally derived substances like neoschaftoside offer a promising alternative. Their application in the development of eco-friendly therapeutic agents aligns with an increasing demand for sustainability in pharmaceutical manufacturing.

Equipped with encouraging data from their experiments, the researchers revealed their hopes of advancing neoschaftoside into clinical trials. Such a transition from the laboratory bench to the clinical setting represents a critical step in validating the therapeutic efficacy of neoschaftoside among a broader population. As the research community anticipates the outcome of these trials, the groundwork laid by this initial study provides a beacon of hope in the relentless battle against lung cancer.

Furthermore, the study highlights the importance of interdisciplinary collaboration in cancer research. By incorporating expertise from multiple fields, including molecular biology, pharmacology, and bioinformatics, the researchers were able to paint a comprehensive picture of neoschaftoside’s action in lung cancer. This model of collaboration is essential moving forward as the complexity of cancer biology necessitates diverse approaches to decipher its challenges.

As the findings circulate within the scientific community, discussions regarding the regulatory and ethical considerations associated with the clinical application of neoschaftoside are inevitable. The transition of botanical compounds from traditional remedies to contemporary medicine must be addressed through rigorous scientific evaluations and adherence to regulatory frameworks. Ensuring that the therapeutic potentials of natural compounds are maximized while safeguarding patient safety will be paramount.

Ultimately, the research conducted by Gudasi and colleagues serves as a testament to the potential of natural compounds in cancer treatment. By uncovering the intricate mechanisms of neoschaftoside, the team has not only highlighted its potential efficacy against lung cancer but has also contributed to a broader understanding of how natural products can be integrated into modern oncology practices. As new avenues of research emerge, the hope is that discoveries like these will indeed translate into tangible benefits for patients suffering from the debilitating effects of cancer.

This pivotal study makes an important contribution to the discourse surrounding alternative cancer treatment strategies. As more researchers delve into the study of natural products, the scientific community stands at the brink of a renaissance in cancer therapy, one that could significantly enhance the quality of life and outcomes for patients afflicted by this pervasive disease.

The journey is far from over, but every step taken towards understanding and utilizing compounds like neoschaftoside reaffirms the commitment of the research community to providing innovative solutions to age-old health challenges. As the findings gain traction, both within academic circles and in clinical settings, they reinforce the notion that hope is on the horizon for lung cancer therapeutics.

Subject of Research: Neoschaftoside from Ailanthus altissima as a targeted therapy for lung cancer.

Article Title: Decoding the molecular mechanism via systems biology-based insights into neoschaftoside from Ailanthus altissima targeting lung cancer.

Article References:

Gudasi, S., Kumar, D., Tewari, S. et al. Decoding the molecular mechanism via systems biology-based insights into neoschaftoside from Ailanthus altissima targeting lung cancer. Sci Rep (2025). https://doi.org/10.1038/s41598-025-33214-0

Image Credits: AI Generated

DOI: 10.1038/s41598-025-33214-0

Keywords: Neoschaftoside, Ailanthus altissima, lung cancer, systems biology, phytochemicals, natural compounds, cancer therapy.

Medicinal plants have been employed in various cultures for centuries, renowned not only for their healing properties but also for their complexity in chemical composition. The study by Bansal et al. highlights that these plants serve as a rich source of bioactive compounds which possess the capacity to combat cancer through multiple mechanisms, including anti-inflammatory, antioxidant, and apoptosis-inducing effects. The researchers emphasize that as the landscape of cancer therapy evolves, integrating these plant-derived compounds can potentially complement and enhance existing treatment modalities, achieving a more holistic approach to patient care.

At the heart of their research lies metabolomics—a cutting-edge scientific discipline that compiles a comprehensive analysis of metabolites within biological specimens. For the first time, Bansal and colleagues demonstrate how this analytical technique can systematically map out the intricate network of metabolite profiles present in medicinal plants. By employing various analytical tools, such as mass spectrometry and nuclear magnetic resonance, the team meticulously identifies active constituents that contribute to anticancer activity. This enables not only the understanding of the pharmacological potential of these compounds but also the refinement of their therapeutic applications.

The researchers also bring to light the compound diversity found within plant species, underscoring the importance of conducting extensive phytochemical screenings. Through these assessments, they identified several key compounds with potent anticancer capabilities, including flavonoids, alkaloids, and terpenoids. Such compounds have been shown to inhibit cancer cell proliferation, induce cell cycle arrest, and trigger programmed cell death, providing a multifaceted approach to cancer treatment. The paper details how this dynamic array of chemical constituents allows for the possibility of synergistic effects when plants are used in combination, potentially maximizing therapeutic outcomes.

Moreover, Bansal et al. stress the significant role of traditional knowledge and ethnopharmacology in guiding modern research. Many ancient cultures have documented the uses of various plants in treating ailments, including cancer. By integrating this ancestral wisdom with contemporary scientific methods, researchers can more effectively target the bioactive compounds responsible for therapeutic effects. This holistic approach not only bridges the gap between tradition and modernity but also champions the importance of preserving indigenous knowledge in an increasingly globalized world.

A compelling aspect of the study is its advocacy for sustainable practices when utilizing medicinal plants. With a growing awareness of the importance of biodiversity, the authors caution against over-harvesting wild species, highlighting the need for responsible cultivation. This is particularly paramount given that many valuable plants are endemic to specific regions and ecosystems. Through sustainable harvesting and cultivation practices, researchers can ensure the continued availability of these vital resources while promoting biodiversity conservation.

The research also addresses challenges related to bioavailability and the pharmacokinetics of plant-derived compounds. Many bioactive metabolites show limited absorption and efficacy when administered orally. The authors propose innovative solutions, such as nanoparticle formulations and enhanced delivery systems, to overcome these barriers and improve the therapeutic potential of medicinal plants. By focusing on innovative methodologies in drug formulation, the researchers pave the way for a new generation of phytopharmaceuticals that can be seamlessly integrated into existing treatment protocols.

A key highlight from the study is the emphasis on the collaborative synergy between phytochemical research and clinical applications. The authors envision a future where traditional plant medicines are widely accepted within the realms of oncology, supported by rigorous scientific validation and clinical trials. Such an integration will not only benefit patients seeking holistic care options but also provide a robust foundation for developing novel cancer therapies derived from nature. The study shines a light on the promising implications for patient outcomes, particularly concerning quality of life and treatment resilience.

As the research landscape evolves, Bansal et al. call for increased investment in this area—particularly in terms of funding for clinical trials that focus on herbal medicines and their effects on cancer treatment. They passionately advocate for a united front among oncologists, pharmacologists, and herbalists to create collaborative frameworks that foster knowledge exchange and interdisciplinary research. This will drive a more nuanced understanding of how medicinal plants can be effectively utilized in modern oncology.

The insights derived from this research are not merely academic; they bear significant implications for global health initiatives aimed at combatting cancer. With the World Health Organization continuously highlighting the increasing burden of cancer across various demographics, leveraging the advancements in metabolomics and phytomedicine could redefine cancer treatment paradigms worldwide. There exists a critical need for the medical community to embrace and explore these avenues further.

In conclusion, Bansal, Alaseem, Babu, and their team are at the forefront of a groundbreaking movement—one that acknowledges the extraordinary potential of medicinal plants while merging it with state-of-the-art scientific methodologies. Their study, which meticulously investigates the intricate networks of metabolites in medicinal flora, offers a hopeful glimpse into the future of cancer treatment. As the realms of traditional medicine converge with modern scientific inquiry, we find ourselves on the precipice of a new frontier in cancer therapeutics, promising enriching avenues for patient care and improved health outcomes.

This pioneering research stands as a clarion call to the scientific community and society at large to recognize and invest in the underexplored potential of plant-based therapies, thus pushing the boundaries of what is possible in the fight against cancer.

Subject of Research: Anticancer potential of medicinal plants

Article Title: Unveiling the anticancer potential of medicinal plants: metabolomics and analytical tools in phytomedicine

Article References:

Bansal, N., Alaseem, A.M., Babu, A.M. et al. Unveiling the anticancer potential of medicinal plants: metabolomics and analytical tools in phytomedicine. Mol Divers (2025). https://doi.org/10.1007/s11030-025-11362-9

Image Credits: AI Generated

DOI:

Keywords: Anticancer, medicinal plants, metabolomics, phytomedicine, bioactive compounds, herbal medicine, cancer treatment, ethnopharmacology, sustainability, phytotherapy.